Japanese encephalitis (JE) is preventable using the affordable, effective, and safe live attenuated SA 14-14-2 JE vaccine (CD-JEV). We used a Markov model to evaluate the cost-effectiveness of 1 dose of CD-JEV compared with no vaccination in 3 vaccination strategies in Bangladesh: subnational campaign and routine immunization, subnational campaign and national routine immunization, and national routine immunization alone. For input parameters, we gathered information from a cost-of-illness study, medical literature, government documents, and expert opinions. The base-case analysis estimated that a subnational campaign for children <15 years of age and routine immunization over 20 birth cohorts in Rajshahi, Rangpur, and Chattogram yielded (in 2021 US dollars) a cost of $82.2 million, $981/disability-adjusted life years averted, $9,964/case averted, and $49,819/death averted (societal perspective). We projected CD-JEV vaccination would be cost-effective across cost perspectives and vaccination strategies in Bangladesh, yielding an incremental cost-effectiveness ratio of approximately one third of per capita national gross domestic product.

使用经济实惠、有效且安全的 SA 14-14-2 JE 减毒活疫苗 （CD-JEV） 可以预防乙型脑炎 （JEV）。我们使用马尔可夫模型来评估孟加拉国 3 种疫苗接种策略中 1 剂 CD-JEV 与不接种疫苗相比的成本效益：地方运动和常规免疫、地方运动和国家常规免疫，以及单独国家常规免疫。对于输入参数，我们从疾病成本研究、医学文献、政府文件和专家意见中收集了信息。基本案例分析估计，在 Rajshahi、Rangpur 和 Chattogram 对 <15 岁儿童进行次国家级运动和 20 个出生队列的常规免疫接种产生了 8220 万美元的成本（以 2021 年美元计算），避免了 981 美元/残疾调整生命年，避免了 9,964 美元/病例，避免了 49,819 美元/死亡（社会角度）。我们预计孟加拉国的 CD-JEV 疫苗接种从成本角度和疫苗接种策略来看都具有成本效益，产生的增量成本效益比约为全国人均国内生产总值的三分之一。